S&P Futures
5,904.00 -2.00 (-0.03%) Dow Futures
43,532.00 +14.00 (+0.03%) Nasdaq Futures
20,457.75 -25.75 (-0.13%) Russell 2000 Futures
2,292.80 +1.60 (+0.07%) Crude Oil
69.68 +0.46 (+0.66%) Gold
2,742.90 +12.90 (+0.47%)
PHAXIAM Therapeutics S.A. (PHXM.PA)
- GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056 226 9326 226 683May 31, 20246 075 1056 226 9896 226 740July 1, 20249 980 66810
- GlobeNewswire
PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study
A Phase 2 study sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)Evaluation of the efficacy of a local treatment with PHAXIAM’s anti-S. aureus phages added to the standard treatment by surgery and antibiotics 80 patients to be enrolled in 27 French clinical centersValidation of the study protocol by the ANSM expected in H1 2025 Lyon (France), October 9, 2024 – 06:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471
